Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
about
Tumor immunotargeting using innovative radionuclidesThe elements of life and medicinesIn Vivo Radionuclide Generators for Diagnostics and TherapySafety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.The potential and hurdles of targeted alpha therapy - clinical trials and beyond.Radioimmunotherapy with α-particle-emitting radionuclides.Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial.Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor XenograftsTargeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.Antibody-mediated delivery of therapeutics for cancer therapy.B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy.claMP Tag: a versatile inline metal-binding platform based on the metal abstraction peptide.Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection.Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.Targeted and Nontargeted α-Particle Therapies.212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.
P2860
Q28083230-7398450F-0B58-4339-BF34-F477B0F8D97AQ28649323-EB0CBA50-2C05-4976-8421-53BB1A95F574Q28818650-FB81B27B-0A5F-4C77-9EC6-F13A67D317A1Q30490448-6AD3B807-7A61-45B4-B1CE-75CA7CC6CBCEQ33629621-51199E8E-400B-4475-9FC7-9B6356A43BD4Q33761180-4BBC72DE-4AC1-4C16-BA94-3FE0F2EB3F4BQ34277296-F869A0AD-4B93-49EF-9A53-4A8A1C5EED91Q34399879-A125C274-3A58-4FDF-A6EF-AE02AAAB14CDQ34419562-CF0D0C87-754A-4558-AE00-D44F61D6E4E0Q35800092-44E2C4ED-2F10-4A25-BE36-885CE48B0E4BQ35818377-80D37454-15C8-49BC-B3D9-5DF45EE7079AQ36088727-C0C65612-C7B3-4BAD-985A-3DF2D9AF1EFEQ36105801-2C1300CB-C7F2-4596-BF23-0F21DF899901Q36105805-B3647992-CD5A-4B71-81F8-A8742677EC60Q36213374-651A4AA1-315A-4DE7-92BF-DC8A3CF2EC46Q36551498-E81FF60C-1FD6-42A3-A158-BF13FFE32C8AQ36939290-87BC19F2-58D4-4F45-A011-0A7E990BEE5EQ37085052-13447D73-E09C-40FC-807F-F56B1607EE38Q38230884-836CB267-2EAD-4EA3-BC14-97C963F97E29Q38663041-24A1C489-84CB-4294-BE41-80396B0902EEQ38665425-210E90A2-1E30-4BF8-8014-4D5C23DD45FCQ38768316-487DCF70-339A-4075-8C91-D2A331349348Q40967736-341A1E84-9C6B-47FB-B370-4BB83EDAEFA2Q42970520-78477FEF-6773-4DF3-ACB8-4493238ED67EQ47152190-06844E9F-2835-4670-8129-246598735547Q48089417-742685D4-BF49-4C3C-82B1-814F4BF0D0D6Q48136353-9CAEA9F7-AE1E-4994-9052-B460EC3404D9Q49967540-654DB58F-FE1C-48A6-8909-D78E7E16E1EBQ50138482-29550144-12DA-4AC7-8E42-4BDBED081710
P2860
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@en
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@nl
type
label
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@en
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@nl
prefLabel
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@en
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and imaging o ...... on in ovarian cancer patients.
@en
P2093
Daniel Yoder
Eileen Banaga
Julien Torgue
Michael T Azure
Patty Bunch
Ronald Alvarez
Ronda Carlise
Ruby F Meredith
Souheil Saddekni
P2860
P356
10.1089/CBR.2013.1531
P50
P577
2013-11-14T00:00:00Z